KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint. PMID 40651005 · J Crohns Colitis · 2025-Sep-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of preoperative immunonutrition vs standard oral nutrition in patients undergoing colorectal surgery: A randomized controlled trial. PMID 41024777 · World J Gastrointest Surg · 2025-Sep-27 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Alzheimer's disease outlook: controversies and future directions. PMID 40997840 · Lancet · 2025-Sep-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. PMID 40976249 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. PMID 40897189 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. PMID 40897188 · Lancet · 2025-Sep-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Therapeutic effect and mechanism of sivelestat sodium on acute lung injury: A randomized controlled trial. PMID 41029079 · Medicine (Baltimore) · 2025-Sep-26 The study is a randomized controlled trial of a drug (sivelestat sodium) for acute lung injury, not a human malignant neoplasm. It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypothermic oxygenated perfusion (HOPE) against cancer recurrence after liver transplantation for hepatocellular carcinoma-study protocol for an international multicenter randomized controlled trial (HOPE4Cancer). PMID 41013675 · Trials · 2025-Sep-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. PMID 41006384 · Sci Rep · 2025-Sep-26 The record is a secondary biomarker analysis from a phase III trial. It is not the original formal report of the randomized trial's primary or key secondary efficacy results. Therefore, it does not meet the inclusion criteria for an original result report of a Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial. PMID 41005350 · J Natl Compr Canc Netw · 2025-Sep-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment and recovery from opioid use disorder: The role of pain severity in individuals with moderate to severe pain. PMID 41046662 · Drug Alcohol Depend · 2025-Sep-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
School-based group interpersonal therapy for adolescents with depression in nepal: protocol for a phase III realist cluster-randomised controlled trial. PMID 40999412 · BMC Psychiatry · 2025-Sep-25 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase II randomised controlled basket feasibility trial of a personalised, remotely delivered exercise programme on disease-free survival among early-stage, high-risk cancers: CANFit study protocol. PMID 40998437 · BMJ Open · 2025-Sep-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke. PMID 40616232 · N Engl J Med · 2025-Sep-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. PMID 40411449 · Clin Exp Dermatol · 2025-Sep-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? PMID 41024839 · World J Clin Oncol · 2025-Sep-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prognostic immune nutritional index-based nutritional stratification enhances recovery and survival in gastric cancer: A randomized controlled trial. PMID 41024831 · World J Clin Oncol · 2025-Sep-24 The record describes a randomized controlled trial in gastric cancer evaluating PINI-based nutritional support. However, it does not meet key eligibility criteria: the phase is not specified as Phase III/IIIb or Phase II/III, the intervention is non-drug nutritional support, and the primary endpoint is not a time-to-event efficacy endpoint with Kaplan-Meier or HR analysis. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease. PMID 40993832 · Trials · 2025-Sep-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Caffeine to improve neurodevelopmental outcomes in infants born late preterm (The Latte Trial): study protocol for a randomised controlled trial. PMID 40993821 · Trials · 2025-Sep-24 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. PMID 41096556 · Int J Mol Sci · 2025-Sep-23 The record is not an oncology study; it is a randomized controlled trial of curcumin for liver steatosis in Type 2 Diabetes. It lacks a drug-containing intervention per the criteria, does not have a primary time-to-event efficacy endpoint, and the phase is not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. PMID 40674744 · Blood Adv · 2025-Sep-23 未发现恶性肿瘤人群证据。
H L S B
旧组与严格 v3 交集 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia. PMID 40505060 · Blood Adv · 2025-Sep-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis. PMID 41010884 · J Clin Med · 2025-Sep-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Protocol for development of SPIRIT and CONSORT extensions for reporting climate and environmental outcomes in randomised trials (SPIRIT-ICE and CONSORT-ICE). PMID 40976669 · BMJ Open · 2025-Sep-21 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial. PMID 41012186 · Vaccines (Basel) · 2025-Sep-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. PMID 40544435 · N Engl J Med · 2025-Sep-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials. PMID 41010726 · J Clin Med · 2025-Sep-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tumour-Infiltrating Lymphocytes, Tumour Cell Density, and Response to Neoadjuvant Short-Course Radiotherapy in Rectal Cancer: A Translational Sub-Study from the MRC CR07 Clinical Trial. PMID 41008883 · Cancers (Basel) · 2025-Sep-17 The study is a translational sub-study of the MRC CR07 trial, analyzing biomarkers (TCD and TIL) in a randomized trial of radiotherapy versus surgery. The intervention does not contain a drug, and the report focuses on biomarker prognostic/predictive value, not the primary efficacy analysis of a drug-containing Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy. PMID 40967677 · BMJ Open Ophthalmol · 2025-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phenomapping-derived selection of fractional flow reserve or optical coherence tomography to personalise percutaneous coronary intervention. PMID 40967674 · Open Heart · 2025-Sep-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial. PMID 40056158 · Neuro Oncol · 2025-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Psychedelics for major depression-From controlled research settings into broader clinical use. PMID 40961925 · Cell Rep Med · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial. PMID 40960153 · Chin Med J (Engl) · 2025-Sep-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review. PMID 40956449 · Cancer Chemother Pharmacol · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
CHOSEN: A Randomized Controlled Feasibility Trial. PMID 40932100 · J Am Heart Assoc · 2025-Sep-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. PMID 40839372 · JAMA · 2025-Sep-16 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial. PMID 40795846 · Cell Rep Med · 2025-Sep-16 The study is an oncology randomized trial with a drug intervention (berberine) and reports original results on adenoma recurrence. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III; it is an extended follow-up of a previous trial, but the original trial's phase is not specified in the record. The primary endpoint is adenoma recurrence (a categorical outcome), not a time-to-event endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. PMID 40079835 · Clin Infect Dis · 2025-Sep-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial. PMID 40036375 · Clin Infect Dis · 2025-Sep-16 The record is excluded because it lacks an explicit time-to-event primary/key secondary efficacy endpoint. The primary endpoint is histological resolution (binary), and while recurrence is analyzed with a log-rank test, the abstract does not provide KM estimates, medians, or HRs, so a time-to-event signal cannot be reliably established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. PMID 39919037 · J Clin Endocrinol Metab · 2025-Sep-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-Term Survival in Gastric Cancer: A Randomized Controlled Trial. PMID 40954394 · Ann Surg Oncol · 2025-Sep-15 The study is a randomized, oncology, human trial with primary time-to-event endpoints (DFS, OS) and original results. However, it does not meet the core eligibility requirement of a drug-containing intervention, as the intervention is psychological and nutritional support, not a pharmacological agent. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Two-Week Course versus Conventionally Fractionated Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision in Locally Advanced Rectal Cancer (Twoarc Trial): A Phase III Randomized Clinical Trial. PMID 40939157 · Ann Surg · 2025-Sep-15 The study is a Phase III randomized trial with drug intervention, but its primary endpoint is pathologic response (downstaging rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier or HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. PMID 40705396 · Clin Cancer Res · 2025-Sep-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer. PMID 40567214 · Gut Liver · 2025-Sep-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study. PMID 40462641 · Gut Liver · 2025-Sep-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. PMID 40339720 · J Affect Disord · 2025-Sep-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Flap sparing in postoperative radiotherapy versus standard flap-agnostic radiotherapy of oral cavity cancers (OPTIFLAP): protocol for a de-escalation, randomised, non-inferiority, phase III trial. PMID 40953868 · BMJ Open · 2025-Sep-14 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Trajectories of Recovery after Intravenous propofol versus inhaled VolatilE anaesthesia (THRIVE) randomised controlled trial in the USA: A protocol. PMID 40953862 · BMJ Open · 2025-Sep-14 The record is a protocol for a randomised trial comparing anaesthetic techniques (propofol vs. volatile anaesthesia) in patients undergoing non-cardiac surgery. It is not an oncology trial, the primary endpoint is a patient-reported recovery score (QOR-15), and it reports no results. Therefore, it fails the core eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III, Randomized, Double-Blind, Active-Controlled Clinical Trial. PMID 41012176 · Vaccines (Basel) · 2025-Sep-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Immunogenicity of Single-Dose of Adsorbed Tetanus Vaccine in Adults Aged 18-44 Years: Randomized, Double-Blind, Positive-Controlled Phase I/III Clinical Trial. PMID 41012175 · Vaccines (Basel) · 2025-Sep-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -